Kestra Medical Technologies, Ltd. (NASDAQ:KMTS – Get Free Report) insider Brian Daniel Webster sold 13,017 shares of Kestra Medical Technologies stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $23.92, for a total transaction of $311,366.64. Following the completion of the transaction, the insider owned 527,115 shares in the company, valued at approximately $12,608,590.80. This trade represents a 2.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Brian Daniel Webster also recently made the following trade(s):
- On Friday, July 31st, Brian Daniel Webster sold 8,948 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.60, for a total transaction of $202,224.80.
- On Thursday, July 30th, Brian Daniel Webster sold 7,857 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.72, for a total transaction of $178,511.04.
- On Monday, June 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $20.81, for a total transaction of $312,150.00.
- On Friday, May 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $20.96, for a total value of $314,400.00.
Kestra Medical Technologies Price Performance
Shares of NASDAQ KMTS opened at $23.99 on Tuesday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41. Kestra Medical Technologies, Ltd. has a one year low of $14.10 and a one year high of $30.00. The firm has a market capitalization of $1.41 billion, a P/E ratio of -9.91 and a beta of 0.58. The company’s fifty day moving average is $22.62 and its two-hundred day moving average is $22.48.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on KMTS shares. Wall Street Zen cut Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a report on Wednesday, July 15th. BTIG Research raised their target price on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. The Goldman Sachs Group cut their target price on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Finally, Weiss Ratings downgraded shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 16th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $27.83.
Check Out Our Latest Stock Analysis on Kestra Medical Technologies
Hedge Funds Weigh In On Kestra Medical Technologies
Institutional investors have recently made changes to their positions in the stock. Farther Finance Advisors LLC acquired a new stake in shares of Kestra Medical Technologies during the fourth quarter valued at $31,000. Russell Investments Group Ltd. raised its stake in Kestra Medical Technologies by 43.5% in the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after purchasing an additional 474 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in Kestra Medical Technologies by 148.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after purchasing an additional 1,638 shares in the last quarter. Daiwa Securities Group Inc. acquired a new stake in shares of Kestra Medical Technologies during the 4th quarter worth about $72,000. Finally, Brown Brothers Harriman & Co. boosted its stake in shares of Kestra Medical Technologies by 26.8% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after purchasing an additional 656 shares during the last quarter.
Key Kestra Medical Technologies News
Here are the key news stories impacting Kestra Medical Technologies this week:
- Neutral Sentiment: Multiple executives, including CFO Vaseem Mahboob and insiders Brian Daniel Webster, Traci S. Umberger, Alfred J. Ford Jr. and Timothy P. Moran, sold shares between July 30 and August 3. The transactions totaled approximately 103,000 shares and more than $2.3 million at prices near $22.60–$23.92. Each filing states that the sales were made to cover tax-withholding obligations tied to vested equity awards, rather than for discretionary investment purposes. SEC insider transaction filings
- Negative Sentiment: The breadth of the selling—including transactions by the CFO and several other insiders—could weigh on sentiment because it reduces management ownership and creates a perception of insider selling pressure. However, the relatively small percentage reductions in most positions and the disclosed tax-related purpose make the signal less bearish than open-market sales based on an expectation of weaker business performance.
Kestra Medical Technologies Company Profile
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.
Read More
- Five stocks we like better than Kestra Medical Technologies
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for Kestra Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kestra Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
-logo.png){kind=logo}
